I earned undergraduate and master’s degrees in physiology from the University of Delaware, followed by a doctorate in cardiovascular physiology at Temple University. My post-doctoral fellowship in Dr. Steve Houser's lab at Temple University Medical School focused on cutting-edge research into the role of CaMKII in heart failure progression. Specifically, I investigated its impact on altered contractility, myocyte apoptosis, and transcriptional regulation. This work was published in Circulation Research and honored as a best manuscript by the journal's editorial board in 2010. In recognition of my contributions to the field, I received the Young Investigator of the Year award from the International Society for Heart Research in 2008.

Prior to joining Regeneron, I spent eight years as a principal scientist in the CardioMetabolic Disease Research department at Boehringer Ingelheim. My work there centered on developing novel therapeutic treatments for chronic kidney disease, heart failure, and fibrosis. In 2016, I transitioned to Regeneron, where I initially managed in-vitro cell biology efforts across cardiovascular, pulmonary, and fibrosis research programs. I also led the cardiac sub-team and histology efforts. Currently, I head a team within the Immunology and Inflammation Therapeutic Focus Area, where we explore innovative approaches to addressing autoimmunity, ulcerative colitis, Crohn’s disease, fibrosis, and immune suppression through technologies such as bi-specific antibodies, tissue-specific receptor activation, and cell medicine.

Beyond my research, I am deeply committed to mentorship and outreach. I actively mentor young scientists, serve as a scientific lead for Regeneron’s high school mentorship program, and contribute as a steering committee member at the New York Academy of Science.